Summary of Study ST001408
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000964. The data can be accessed directly via it's Project DOI: 10.21228/M83406 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST001408 |
| Study Title | Metabolomic profiling of baseline plasmas from a longitudinal prospective cohort of 491 active surveillance (AS) participants |
| Study Type | Biomarker study |
| Study Summary | Untargeted metabolomics analyses were performed on clinically matched baseline plasma samples (n = 16 per group) prospectively collected from patients with clinically low-risk early stage prostate cancer undergoing AS who exhibited early disease progression (DP) (defined as upgrading of Gleason score (GS) and/or increased tumor volume on surveillance biopsy within 18 months after start of AS) or indolent disease (no progression for five or more years after start of AS) as well as 459 baseline plasma samples prospectively collected from patients with early-stage prostate cancer undergoing AS. |
| Institute | University of Texas MD Anderson Cancer Center |
| Department | Department of Clinical Cancer Prevention |
| Last Name | Vykoukal |
| First Name | Jody |
| Address | 6767 Bertner Ave, Houston, TX 77030 |
| jvykouka@mdanderson.org | |
| Phone | 713-834-6095 |
| Submit Date | 2020-05-19 |
| Raw Data Available | Yes |
| Analysis Type Detail | LC-MS |
| Release Date | 2020-07-02 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Combined analysis:
| Analysis ID | AN002352 | AN002353 | AN002354 |
|---|---|---|---|
| Analysis type | MS | MS | MS |
| Chromatography type | HILIC | Reversed phase | Reversed phase |
| Chromatography system | Waters Acquity UPLC | Waters Acquity UPLC | Waters Acquity UPLC |
| Column | Waters Acquity UPLC BEH amide,(100 x 2.1mm,1.7um,100 Å) | Waters ACQUITY UPLC HSS T3 (100 x 2.1mm,1.8um,100 Å) | Waters ACQUITY UPLC HSS T3 (100 x 2.1mm,1.8um,100 Å) |
| MS Type | ESI | ESI | ESI |
| MS instrument type | QTOF | QTOF | QTOF |
| MS instrument name | Waters Xevo G2-XS | Waters Xevo G2-XS | Waters Xevo G2-XS |
| Ion Mode | POSITIVE | POSITIVE | POSITIVE |
| Units | normalized ion abundance | normalized ion abundance | normalized ion abundance |
MS:
| MS ID: | MS002194 |
| Analysis ID: | AN002352 |
| Instrument Name: | Waters Xevo G2-XS |
| Instrument Type: | QTOF |
| MS Type: | ESI |
| MS Comments: | Mass spectrometry data was acquired using ‘sensitivity’ mode in positive and negative electrospray ionization mode within 50-1200 Da range. For the electrospray acquisition, the capillary voltage was set at 1.5 kV (positive), 3.0kV (negative), sample cone voltage 30V, source temperature at 120° C, cone gas flow 50 L/h and desolvation gas flow rate of 800 L/h with scan time of 0.5 sec in continuum mode. Leucine Enkephalin; 556.2771 Da (positive) and 554.2615 Da (negative) was used for lockspray correction and scans were performed at 0.5 min. The injection volume for each sample was 3µL, unless otherwise specified. The acquisition was carried out with instrument auto gain control to optimize instrument sensitivity over the samples acquisition time. LC-MS and LC-MSe data were processed using Progenesis QI (Nonlinear, Waters) and values were reported as area units. |
| Ion Mode: | POSITIVE |
| MS ID: | MS002195 |
| Analysis ID: | AN002353 |
| Instrument Name: | Waters Xevo G2-XS |
| Instrument Type: | QTOF |
| MS Type: | ESI |
| MS Comments: | Mass spectrometry data was acquired using ‘sensitivity’ mode in positive and negative electrospray ionization mode within 50-1200 Da range. For the electrospray acquisition, the capillary voltage was set at 1.5 kV (positive), 3.0kV (negative), sample cone voltage 30V, source temperature at 120° C, cone gas flow 50 L/h and desolvation gas flow rate of 800 L/h with scan time of 0.5 sec in continuum mode. Leucine Enkephalin; 556.2771 Da (positive) and 554.2615 Da (negative) was used for lockspray correction and scans were performed at 0.5 min. The injection volume for each sample was 3µL, unless otherwise specified. The acquisition was carried out with instrument auto gain control to optimize instrument sensitivity over the samples acquisition time. LC-MS and LC-MSe data were processed using Progenesis QI (Nonlinear, Waters) and values were reported as area units. |
| Ion Mode: | POSITIVE |
| MS ID: | MS002196 |
| Analysis ID: | AN002354 |
| Instrument Name: | Waters Xevo G2-XS |
| Instrument Type: | QTOF |
| MS Type: | ESI |
| MS Comments: | Mass spectrometry data was acquired using ‘sensitivity’ mode in positive and negative electrospray ionization mode within 100-2000 Da for complex lipids. For the electrospray acquisition, the capillary voltage was set at 1.5 kV (positive), 3.0kV (negative), sample cone voltage 30V, source temperature at 120° C, cone gas flow 50 L/h and desolvation gas flow rate of 800 L/h with scan time of 0.5 sec in continuum mode. Leucine Enkephalin; 556.2771 Da (positive) and 554.2615 Da (negative) was used for lockspray correction and scans were performed at 0.5 min. The injection volume for each sample was 3µL, unless otherwise specified. The acquisition was carried out with instrument auto gain control to optimize instrument sensitivity over the samples acquisition time. LC-MS and LC-MSe data were processed using Progenesis QI (Nonlinear, Waters) and values were reported as area units. |
| Ion Mode: | POSITIVE |
